Latest Pharmaceutical Investments News

Telix Pharmaceuticals has initiated a US$550 million convertible bonds offering to refinance existing 2029 bonds and support general corporate purposes, securing low-cost, non-dilutive financing with a conversion premium above current share price.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.